Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Vivek Garipalli, a director and 10% owner of Clover Health Investments (CLOV), reported purchases of Class A common stock on 08/07/2025 and 08/08/2025. He acquired 415,000 shares on 08/07/2025 at a weighted average price of $2.24 and 31,980 shares on 08/08/2025 at a weighted average price of $2.17, bringing his reported direct ownership to 1,856,247 Class A shares.
Table II discloses substantial Class B common stock that converts one-for-one into Class A: 6,904,343 Class A-equivalent shares held directly, plus 11,500,000 and 72,084,543 Class A-equivalent shares held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, respectively. The filing states Garipalli serves as sole manager of those LLCs.
Clover Health (CLOV) Q2 2025 10-Q snapshot
Premiums climbed 34% YoY to $469.8 m, lifting total revenue to $477.6 m, yet net medical claims surged 52% to $378.0 m, pushing the medical loss ratio to ~80.5% (71% in Q2 2024). Operating loss was $10.6 m versus prior-year profit of $7.2 m; GAAP EPS fell to –$0.02.
First-half revenue rose 34% to $939.9 m while net loss narrowed to $11.9 m (–$0.02 EPS) from $16.0 m, aided by a $2.8 m favourable prior-year claims development. Stock-based compensation remained high at $52.6 m YTD.
Cash & equivalents ended at $188.6 m, down $5.9 m YTD. Operating cash flow swung to a $10.9 m outflow (vs. $79.7 m inflow last year); investing inflows of $44.5 m offset $39.5 m used for equity-related financing. Total assets were $575 m and equity improved to $344 m.
Unpaid claims declined 11% YTD to $139.7 m; investment portfolio posted a $1.8 m unrealised gain, turning OCI positive. Weighted-average diluted shares stood at 509 m.
Management continues to expand Clover Assistant and Counterpart Health SaaS but flags medical cost inflation, RADV audit exposure and regulatory uncertainty as key risks.